SPOP and neoplasm: The study of some of these patients with hormone-naïve and castration-resistant tumor samples established 17% CHD1 loss in tumor biopsies; CHD1 loss and/or SPOP mutations were associated with a higher response rate to Abiraterone and a longer time on Abiraterone [136,146].